KR20230047201A - 15-hepe를 포함하는 조성물 및 그의 사용 방법 - Google Patents

15-hepe를 포함하는 조성물 및 그의 사용 방법 Download PDF

Info

Publication number
KR20230047201A
KR20230047201A KR1020237009963A KR20237009963A KR20230047201A KR 20230047201 A KR20230047201 A KR 20230047201A KR 1020237009963 A KR1020237009963 A KR 1020237009963A KR 20237009963 A KR20237009963 A KR 20237009963A KR 20230047201 A KR20230047201 A KR 20230047201A
Authority
KR
South Korea
Prior art keywords
ohepa
present
fatty liver
disease
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237009963A
Other languages
English (en)
Korean (ko)
Inventor
조나단 로우
케빈 더피
존 클라이맥스
Original Assignee
애피뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애피뮨 리미티드 filed Critical 애피뮨 리미티드
Priority to KR1020247001131A priority Critical patent/KR20240011872A/ko
Publication of KR20230047201A publication Critical patent/KR20230047201A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
KR1020237009963A 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법 Ceased KR20230047201A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247001131A KR20240011872A (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1301626.6 2013-01-30
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same
KR1020227028323A KR102514913B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227028323A Division KR102514913B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001131A Division KR20240011872A (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법

Publications (1)

Publication Number Publication Date
KR20230047201A true KR20230047201A (ko) 2023-04-06

Family

ID=47891001

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020237009963A Ceased KR20230047201A (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020257022099A Pending KR20250105691A (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020247001131A Ceased KR20240011872A (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020217020740A Active KR102434817B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020227028323A Active KR102514913B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020157020952A Active KR102274963B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020257022099A Pending KR20250105691A (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020247001131A Ceased KR20240011872A (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020217020740A Active KR102434817B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020227028323A Active KR102514913B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법
KR1020157020952A Active KR102274963B1 (ko) 2013-01-30 2014-01-24 15-hepe를 포함하는 조성물 및 그의 사용 방법

Country Status (27)

Country Link
US (6) US20150224076A1 (enExample)
EP (2) EP2762143B1 (enExample)
JP (2) JP6363104B2 (enExample)
KR (6) KR20230047201A (enExample)
CN (2) CN111214464A (enExample)
AU (2) AU2014211628B2 (enExample)
BR (1) BR112015018270A2 (enExample)
CA (1) CA2897343C (enExample)
CY (1) CY1117209T1 (enExample)
DK (1) DK2762143T3 (enExample)
ES (2) ES2564025T3 (enExample)
GB (1) GB201301626D0 (enExample)
HR (1) HRP20160203T1 (enExample)
HU (1) HUE026901T2 (enExample)
IL (3) IL239893A (enExample)
MX (2) MX364646B (enExample)
NZ (1) NZ709803A (enExample)
PH (1) PH12015501582B1 (enExample)
PL (1) PL2762143T3 (enExample)
PT (1) PT2762143E (enExample)
RS (1) RS54584B1 (enExample)
RU (2) RU2671208C2 (enExample)
SG (2) SG11201505457PA (enExample)
SI (1) SI2762143T1 (enExample)
SM (1) SMT201600069B (enExample)
WO (1) WO2014118097A1 (enExample)
ZA (2) ZA201505018B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2019110980A (ru) * 2014-01-10 2019-08-26 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
EP4218736A3 (en) * 2015-12-18 2023-10-18 Afimmune Limited Compositions comprising 15-hepe
PT3720431T (pt) 2017-12-06 2024-12-05 Basf As Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU3846801A (en) * 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
MXPA03010888A (es) 2001-05-30 2004-02-27 Laxdale Ltd Coenzimas q y acido eicosapentaenoico (epa).
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
WO2008021192A2 (en) 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
EP2143430B1 (en) * 2007-03-30 2015-09-23 Kowa Company, Ltd. Drug for preventing and/or treating fatty liver or nonalcoholic fatty liver disease
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP5523439B2 (ja) * 2009-02-20 2014-06-18 国立大学法人 東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP2607358A4 (en) * 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013082265A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
SG10201701004RA (en) 2012-01-06 2017-04-27 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP2858496B9 (en) 2012-05-10 2023-11-29 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
EP4218736A3 (en) 2015-12-18 2023-10-18 Afimmune Limited Compositions comprising 15-hepe

Also Published As

Publication number Publication date
US20200069626A1 (en) 2020-03-05
JP6363104B2 (ja) 2018-07-25
SMT201600069B (it) 2016-04-29
KR102514913B1 (ko) 2023-03-27
ZA201505018B (en) 2017-01-25
IL265876A (en) 2019-06-30
CN111214464A (zh) 2020-06-02
EP3058943A1 (en) 2016-08-24
JP2018172409A (ja) 2018-11-08
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
IL239893A (en) 2017-04-30
KR20250105691A (ko) 2025-07-08
WO2014118097A1 (en) 2014-08-07
EP3058943B1 (en) 2019-09-25
HUE026901T2 (en) 2016-07-28
US20210244697A1 (en) 2021-08-12
HK1200351A1 (en) 2015-08-07
AU2018206685A1 (en) 2018-08-02
IL239893A0 (en) 2015-08-31
SG11201505457PA (en) 2015-08-28
CY1117209T1 (el) 2017-04-05
PT2762143E (pt) 2016-03-28
CN105120872B (zh) 2020-01-10
CA2897343A1 (en) 2014-08-07
KR20220119524A (ko) 2022-08-29
SI2762143T1 (sl) 2016-04-29
EP2762143A1 (en) 2014-08-06
CA2897343C (en) 2021-03-16
US20150224076A1 (en) 2015-08-13
ZA201605125B (en) 2018-06-27
AU2014211628B2 (en) 2018-04-19
CN105120872A (zh) 2015-12-02
IL251639A0 (en) 2017-06-29
MX2019005082A (es) 2019-08-12
KR102434817B1 (ko) 2022-08-19
NZ709803A (en) 2020-05-29
RU2671208C2 (ru) 2018-10-30
MX364646B (es) 2019-05-03
JP2016511753A (ja) 2016-04-21
KR20210088733A (ko) 2021-07-14
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
DK2762143T3 (en) 2016-03-07
PH12015501582A1 (en) 2015-10-05
BR112015018270A2 (pt) 2017-07-18
ES2564025T3 (es) 2016-03-17
AU2014211628A1 (en) 2015-07-30
KR102274963B1 (ko) 2021-07-08
PL2762143T3 (pl) 2016-06-30
ES2759448T3 (es) 2020-05-11
GB201301626D0 (en) 2013-03-13
KR20150112995A (ko) 2015-10-07
RU2015136849A (ru) 2017-03-06
US10813903B2 (en) 2020-10-27
HRP20160203T1 (hr) 2016-03-25
SG10201806854XA (en) 2018-09-27
EP2762143B1 (en) 2015-12-02
RS54584B1 (sr) 2016-08-31
US20220347147A1 (en) 2022-11-03
MX2015009803A (es) 2015-10-29
US20250186384A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
KR102514913B1 (ko) 15-hepe를 포함하는 조성물 및 그의 사용 방법
AU2020267224B2 (en) Compositions comprising 15-HEPE and methods of using the same
AU2015358512B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
HK1200351B (en) Compositions comprising 15-hepe and methods of using the same

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230323

Application number text: 1020227028323

Filing date: 20220817

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230601

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231011

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230601

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I